Amneal Pharmaceuticals (AMRX) reported Q1 preliminary adjusted earnings Wednesday of $0.27 per diluted share, up from $0.21 a year earlier.

Analysts polled by FactSet expected $0.17.

Net revenue for the quarter ended March 31 was $722.5 million, up from $695.4 million a year earlier. Analysts surveyed by FactSet expected $719.7 million.

For full-year 2026, the company continues to expect net revenue in the range of $3.05 billion to $3.15 billion. Analysts polled by FactSet expect $3.10 billion.

For 2026, Amneal raised its adjusted diluted EPS outlook to the range of $0.95 to $1.05, compared with the prior estimate of $0.93 to $1.03. Analysts surveyed by FactSet expect $ 0.99.

Additionally, Amneal said it has entered into a definitive agreement to acquire 100% of Kashiv BioSciences for $375 million of cash and $375 million of equity payable at closing. The agreement also includes up to $350 million in additional payments tied to regulatory and commercial milestones, and funding of operations through closing.

Shares of Amneal were up more than 3% in Wednesday's pre-bell activity.